Dave Domann is Director, Health Policy, Advocacy & Quality at North American Pharmaceuticals for Johnson and Johnson in Titusville, New Jersey where he is responsible for health policy on evidence based medicine and healthcare quality improvement.  In his role, Dave identifies critical health policy issues on comparative effectiveness research, quality measurement / reporting and drives strategies to demonstrate the value of company products/services in the evolving healthcare environment.Dave serves in leadership roles at the National Quality Forum (NQF) as Chairperson of the NQF Supplier / Industry Council and serves on the NQF Leadership Network and the newly formed NQF Education Committee. He was recently selected to represent industry on the NQF Convened National Priority Partnership that is responsible for identifying national quality improvement priorities in the United States.   He also Co-Chairs the Pharmacy Quality Alliance (PQA) Overuse Workgroup and previously co-chaired the Medication Management Integration with the Medical Home Workgroup and Education and Communication Workgroup.  Dave is one of the key authors of a recent Institute of Medicine Roundtable on Evidence-Based Medicine publication on Leadership Commitments to Improve Value in Health Care – Finding Common Ground – Health Product Developers (IOM 2009).Previously, Dave led EBM and Quality Improvement Strategy development in Future Market Strategies at Ortho-McNeil Janssen Pharmaceuticals, Inc.  He also directed related activities in Healthcare Quality Management and Medical Communication departments at Janssen Pharmaceutica and Ortho-McNeil-Janssen Scientific Affairs.  He has pharmacy experience in community, hospital, and long-term care pharmacy consultant environments and served as a member of the Kansas Drug Utilization Review Foundation.